Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
- Demonstrated strong efficacy with 11.0-month median PFS in second-line patients
- High clinical benefit rate of 67% and 39% confirmed objective response rate in measurable disease
- Impressive 67% confirmed ORR in patients with kinase mutations
- Favorable safety profile with 92% median dose intensity and mostly low-grade adverse events
- Advancing to Phase 3 trial (ReDiscover-2) in mid-2025
- Lower PFS (8.5 months) in patients with non-kinase mutations compared to kinase mutations (18.4 months)
- 36% of patients experienced Grade 3 treatment-related adverse events
- Two patients discontinued treatment due to adverse events
Insights
RLY-2608 shows promising 11-month PFS in PI3Kα-mutated breast cancer with favorable safety profile ahead of pivotal Phase 3.
The updated data for RLY-2608 demonstrates sustained clinical efficacy with a 10.3-month median progression-free survival (PFS) overall and 11.0-month median PFS in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. This represents a meaningful clinical benefit in a population with significant unmet needs, particularly since treatment options for CDK4/6-experienced patients with PI3Kα mutations haven't substantially improved in a decade.
The efficacy signals are particularly strong in patients with kinase mutations, who achieved an impressive 18.4-month median PFS in the second-line setting and a 67% confirmed objective response rate among those with measurable disease. The clinical benefit rate of 67% across all patients further substantiates RLY-2608's potential therapeutic value.
The tolerability profile appears substantially better than existing PI3K inhibitors, with predominantly low-grade adverse events that were manageable and reversible. Only 3% of patients experienced Grade 3 hyperglycemia with no Grade 4-5 events - a significant improvement over pan-PI3K inhibitors which typically cause substantial metabolic toxicities. The 92% median dose intensity and low discontinuation rate suggest patients can remain on treatment longer, potentially extending clinical benefit.
The initiation of the pivotal Phase 3 ReDiscover-2 study in mid-2025 represents a critical development milestone, while the ongoing evaluation of triplet combinations with CDK inhibitors (atirmociclib and ribociclib) could potentially expand RLY-2608's therapeutic applications into first-line settings. This comprehensive development strategy addresses both immediate second-line needs and potential future front-line opportunities in breast cancer treatment.
Relay's RLY-2608 data confirms 10+ month PFS with excellent tolerability, supporting key upcoming Phase 3 program.
The updated clinical data for RLY-2608 strengthens Relay's position in the competitive precision oncology landscape. With 12.5 months median follow-up, the consistency of the efficacy data - particularly the 11.0-month median PFS in second-line patients - validates Relay's novel approach to PI3Kα inhibition through allosteric targeting rather than conventional ATP-competitive binding.
The differentiating factor for RLY-2608 is its mutation-selectivity profile, which appears to deliver both efficacy and tolerability advantages. The 18.4-month PFS in kinase-mutated patients suggests potential for a precision medicine approach with biomarker-driven patient selection that could maximize therapeutic benefit. Importantly, the 40% response rate in patients previously treated with fulvestrant indicates RLY-2608 can overcome resistance to standard endocrine therapy.
From a development perspective, Relay is executing a comprehensive strategy with both the upcoming Phase 3 program and exploration of triplet combinations that could expand market potential. The ReDiscover-2 pivotal trial will be the first Phase 3 study of a mutant-selective PI3Kα inhibitor, potentially establishing a new standard of care in this indication.
The parallel development of RLY-2608 in vascular malformations through the ReInspire study represents a second potential indication that could diversify revenue streams. This multi-pronged approach with a single asset exemplifies efficient drug development strategy.
The partnership with Pfizer to evaluate RLY-2608 with atirmociclib (selective-CDK4 inhibitor) also adds strategic value, potentially optimizing the combination of two precision-targeted agents while building important industry relationships.
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Data continue to support planned initiation of pivotal study in mid-2025
Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced updated interim clinical data for RLY-2608, the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα. The updated data have a median duration of follow-up of 12.5 months and remain consistent with data shared in December 2024. They show a median progression free survival (PFS) of 11.0 months in second line (2L) patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer who received RLY-2608 600mg twice daily (BID) + fulvestrant. These data are being presented today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.
“The treatment options for CDK4/6-experienced patients with PI3Kα mutations has not meaningfully advanced in the past 10 years and recent data disclosures and trial discontinuations highlight the level of unmet need in this population. We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care,” said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. “We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year.”
ReDiscover – RLY-2608 First-in-Human Study
RLY-2608 is currently being evaluated in ReDiscover, an ongoing first-in-human study, which was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of RLY-2608 in combination with fulvestrant, and in combination with fulvestrant and ribociclib or atirmociclib (Pfizer’s selective CDK4 inhibitor).
The RLY-2608 + fulvestrant arm of the study, as of the March 26, 2025 interim data cut-off for this arm, had enrolled 118 patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer across all doses in both the dose escalation and dose expansion portions of the study, including 64 patients at the company’s recommended Phase 3 dose (RP3D) of 600mg BID administered in the fasted state (fasted). Among these 64 patients, 31 had a kinase mutation and 33 had a non-kinase mutation. Twelve patients also had a PTEN or AKT co-mutation and were therefore excluded from the efficacy analysis, consistent with the planned pivotal population.
All RLY-2608 + fulvestrant patients across doses had received a significant level of prior therapy in the advanced setting, including at least one prior endocrine therapy and at least one prior CDK4/6 inhibitor. Among the 64 patients who received the RP3D,
The RLY-2608 + atirmociclib + fulvestrant arm of the study, initiated in Q4 2024, continues to enroll patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer in dose escalation, as does the RLY-2608 + ribociclib + fulvestrant arm.
Promising Efficacy Consistently Demonstrating mPFS Greater Than 10 Months
Among the 52 RLY-2608 + fulvestrant patients who received the RP3D and did not have a PTEN or AKT co-mutation:
- Median follow-up was 12.5 months
- The median PFS was 10.3 months for all patients and 11.0 months for 2L patients
- For 2L patients, median PFS was 18.4 months for patients with kinase mutations and 8.5 months for patients with non-kinase mutations
- Clinical benefit rate (CBR) was
67% across all patients (35 of 52 CBR-evaluable patients; CBR defined as the proportion of patients with complete response, partial response or stable disease for at least 24 weeks) - Among the 31 patients with measurable disease, 12 achieved a partial response (PR) (
39% confirmed objective response rate, ORR)81% of patients experienced tumor reductions (25/31)- Among the 15 patients with measurable disease who had a kinase mutation, two thirds achieved a PR (
67% confirmed ORR; n=10) - Among the 15 patients who had received prior fulvestrant, 6 achieved a PR (
40% confirmed ORR)
Maintained Meaningfully Differentiated Tolerability Profile
RLY-2608 + fulvestrant was generally well tolerated in the 118 patients treated across all doses as of the data cut-off date. The overall tolerability profile consisted of mostly low-grade treatment-related adverse events (TRAEs) that were manageable and reversible. Safety outcomes were generally as expected across dose levels based on exposure and consistent with mutant-selective PI3Kα inhibition. Among the 64 patients who received the RP3D:
- The low rate of TRAE-related dose modifications allowed for
92% median dose intensity - Only two patients discontinued treatment due to TRAEs (Grade 1 pruritis; Grade 1 nausea, loss of appetite)
- The majority of hyperglycemia was Grade 1; only two patients (
3% ) experienced Grade 3 hyperglycemia; no Grade 4-5 hyperglycemia - Only
36% of patients experienced a Grade 3 TRAE; no Grade 4-5 TRAEs
Continued Progression of Front-Line Breast Cancer Regimens
Two front-line triplet regimens are being progressed – one with Pfizer’s investigative selective-CDK4 inhibitor atirmociclib and one with the existing CDK4/6 standard-of-care ribociclib. Dose escalation is ongoing for both arms and both are currently at biologically active doses.
Anticipated RLY-2608 Next Steps
- Breast Cancer:
- Initiate Phase 3 ReDiscover-2 (NCT06982521) study of RLY-2608 + fulvestrant in mid-2025
- Continue dose escalation for additional breast cancer combination arms
- Vascular Malformations:
- Continue enrollment of Ph1/2 ReInspire study in vascular malformations
- Continue enrollment of Ph1/2 ReInspire study in vascular malformations
The data presentation from ASCO is available on the Relay Therapeutics website in the “Publications/Presentations” section through the following link: https://relaytx.com/publications/.
About RLY-2608
RLY-2608 is the lead program in Relay Therapeutics’ efforts to discover and develop mutant selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers, with oncogenic mutations detected in about
Traditionally, the development of PI3Kα inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3Kα and off-isoform activity. Toxicity related to inhibition of WT PI3Kα and other PI3K isoforms results in sub-optimal inhibition of mutant PI3Kα with reductions in dose intensity and frequent discontinuation. The Dynamo® platform enabled the discovery of RLY-2608, the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3Kα, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3Kα, and leveraged these insights to support the design of RLY-2608. RLY-2608 is currently being evaluated in a first-in-human study designed to treat patients with advanced solid tumors with a PIK3CA (PI3Kα) mutation. For more information on RLY-2608, please visit here.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics’ strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics’ portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection and the expectations regarding Relay Therapeutics’ use of capital and expenses. The words “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics’ drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics’ ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Relay Therapeutics’ most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
What are the latest clinical trial results for Relay Therapeutics' RLY-2608?
How safe is RLAY's RLY-2608 in combination with fulvestrant?
When will Relay Therapeutics begin Phase 3 trials for RLY-2608?
What is the response rate of RLY-2608 in patients with kinase mutations?
How does RLY-2608 perform in patients previously treated with fulvestrant?
